Ardiente, Emerita A.
HRN: 26-54-91 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/19/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
01/19/2025
01/26/2025
IV
4.5 LD Then 2.25gm
Q8h
DFI, Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes